-
公开(公告)号：US2808412A
公开(公告)日：1957-10-01
申请号：US46813554
申请日：1954-11-10
申请人： EASTMAN KODAK CO
发明人： ARTHUR JEFFREYS ROY
IPC分类号： C07D263/32 , C07D263/46 , C09B23/04 , C09B23/10 , G03C1/12
CPC分类号： G03C1/12 , C07D263/32 , C07D263/46 , C09B23/04 , C09B23/102
-
公开(公告)号：US11608330B2
公开(公告)日：2023-03-21
申请号：US17221549
申请日：2021-04-02
发明人： Caroline Springer , Richard Marais , Dan Niculescu-Duvaz , Leo Leung , Deborah Smithen , Cedric Callens , Haoran Tang
IPC分类号： C07D417/12 , A61P35/00 , C07D263/46 , C07D277/26 , C07D277/36 , C07D333/18 , C07D333/34 , C07D409/12 , C12Q1/37
摘要： Provided are compounds of the Formula (I), or a pharmaceutically acceptable salt thereof: wherein W, X, Y, Z, x, R1, R2, R3, x and n are defined in the specification. The compounds are inhibitors of lysyl oxidase (LOX) and lysyl oxidase-like (LOXL) family members (LOXL1, LOXL2, LOXL3, LOXL4) and are useful in therapy, particularly in the treatment of cancer. Also disclosed are LOX inhibitors for use in the treatment of a cancer associated with EGFR and biomarkers that predict responsiveness to a LOX inhibitor.
-
公开(公告)号：US20230079631A1
公开(公告)日：2023-03-16
申请号：US17662863
申请日：2022-05-11
申请人： Novartis AG
发明人： Luigi FRANCHI , Shomir GHOSH , Gary GLICK , Jason KATZ , Anthony William OPIPARI, JR. , William ROUSH , Hans Martin SEIDEL , Dong-Ming SHEN , Shankar VENKATRAMAN , David Guenther WINKLER
IPC分类号： C07D265/30 , A61P1/00 , A61P11/00 , A61P19/08 , A61P35/00 , C07C381/10 , C07D209/26 , C07D211/78 , C07D215/06 , C07D231/12 , C07D239/26 , C07D239/36 , C07D261/08 , C07D263/46 , C07D277/36 , C07D317/50 , C07D333/34 , C07D401/12 , C07D409/12 , C07D417/12
摘要： In one aspect, compounds of Formula AA, or a pharmaceutically acceptable salt thereof, are featured: or a pharmaceutically acceptable salt thereof, wherein the variables shown in Formula A can be as defined anywhere herein.
-
公开(公告)号：US20220380325A1
公开(公告)日：2022-12-01
申请号：US17363534
申请日：2021-06-30
IPC分类号： C07D263/46 , A61P35/00 , C07D271/113 , C07D261/08 , C07D263/48 , C07D231/38 , C07D239/42 , C07D233/74 , C07D277/36 , C07D277/42 , C07D277/56 , C07D307/64 , C07D241/20 , C07D263/38 , C07D233/84 , C07D233/88 , C07D233/80 , C07D233/76
摘要： The present invention relates to compounds of formula (I)-(VI) and/or (A)-(H-I), or any subgenera thereof, or a pharmaceutically acceptable salt, tautomer or stereoisomer. The compounds of the present disclosure are useful in modulating androgen receptor activity and for treating cancer including prostate cancer.
-
公开(公告)号：US11203579B2
公开(公告)日：2021-12-21
申请号：US16632849
申请日：2018-07-23
申请人： Novartis AG
发明人： Luigi Franchi , Shomir Ghosh , Gary Glick , Jason Katz , Anthony William Opipari, Jr. , William Roush , Hans Martin Seidel , Dong-Ming Shen , Shankar Venkatraman , David Guenther Winkler
IPC分类号： C07D277/36 , C07D307/64 , C07D333/34 , C07C307/06 , C07D215/36 , C07D231/18 , C07D239/26 , C07D263/46 , C07D307/79 , C07D317/62 , C07D487/04 , C07C335/42 , C07D213/71 , C07D231/12 , C07D405/12 , C07D409/12 , C07D417/12 , C07D471/04
摘要： In one aspect, compounds of Formula AA, or a pharmaceutically acceptable salt thereof, are featured. The variables shown in Formula AA are as defined in the claims. The compounds of formula AA are NLRP3 activity modulators and, as such, can be used in the treatment of metabolic disorders (e.g. Type 2 diabetes, atherosclerosis, obesity or gout), a disease of the central nervous system (e.g. Alzheimer's disease, multiple sclerosis, Amyotrophic Lateral Sclerosis or Parkinson's disease), lung disease (e.g. asthma, COPD or pulmonary idiopathic fibrosis), liver disease (e.g. NASH syndrome, viral hepatitis or cirrhosis), pancreatic disease (e.g. acute pancreatitis or chronic pancreatitis), kidney disease (e.g. acute kidney injury or chronic kidney injury), intestinal disease (e.g. Crohn's disease or Ulcerative Colitis), skin disease (e.g. psoriasis), musculoskeletal disease (e.g. scleroderma), a vessel disorder (e.g. giant cell arteritis), a disorder of the bones (e.g. osteoarthritis, osteoporosis or osteopetrosis disorders), eye disease (e.g. glaucoma or macular degeneration), a disease caused by viral infection (e.g. HIV or AIDS), an autoimmune disease (e.g. Rheumatoid Arthritis, Systemic Lupus Erythematosus or Autoimmune Thyroiditis), cancer or aging.
-
公开(公告)号：US20210340114A1
公开(公告)日：2021-11-04
申请号：US17226854
申请日：2021-04-09
IPC分类号： C07D263/46 , A61K31/4418 , A61P27/02 , A61K31/421 , C07D231/22 , C07D239/34 , A61K31/505 , C07D263/38 , C07D213/70 , C07D213/65 , C07D231/12 , A61K31/415 , C07K14/47 , C12N15/09
摘要： Provided is a heterocyclic compound having a superior RBP4-lowering action and useful as a medicament for the prophylaxis or treatment of a disease or symptom mediated by an increase in RBP4 or retinol supplied by RBP4.
A compound represented by the formula (I): wherein each symbol is as defined in the Description, or a salt thereof has a superior RBP4-lowering action, and is useful as a medicament for the prophylaxis or treatment of a disease or symptom mediated by an increase in RBP4 or retinol supplied by RBP4.-
公开(公告)号：US11149033B2
公开(公告)日：2021-10-19
申请号：US16338237
申请日：2017-09-29
发明人： Ji Young Min , So Young Chang , Ji Hye Lee , Sun Hee Kang , Sun Ju Kong , Su Yeon Jo , Young Mi Kim , Junghwan Choi
IPC分类号： C07D413/06 , C07D263/46 , C07D271/10 , C07D271/113 , C07D307/64 , C07D405/06
摘要： The present invention relates to a novel heteroaryl compound, an enantiomer, a diastereomer or a pharmaceutically acceptable salt thereof, and an antiviral composition comprising the same as an active ingredient. The novel compounds represented by formula (I) or formula (II) according to the present invention are remarkably superior in antiviral activity against an influenza virus, and furthermore, have low cytotoxicity and thus low adverse effects on a human body. Therefore, a pharmaceutical composition containing the same as an active ingredient can be effectively used for the prevention or treatment of diseases caused by an influenza virus infection.
-
公开(公告)号：US10807974B2
公开(公告)日：2020-10-20
申请号：US15999458
申请日：2017-02-17
发明人： Caroline Springer , Richard Marais , Dan Niculescu-Duvaz , Leo Leung , Deborah Smithen , Cedric Callens , Haoran Tang
IPC分类号： C07D417/12 , A61P35/00 , C07D333/18 , C07D277/26 , C12Q1/37 , C07D333/34 , C07D277/36 , C07D263/46 , C07D409/12
摘要： Provided are compounds of the Formula (I), or a pharmaceutically acceptable salt thereof: wherein W, X, Y, Z, x, R1, R2, R3, x and n are defined in the specification. The compounds are inhibitors of lysyl oxidase (LOX) and lysyl oxidase-like (LOXL) family members (LOXL1, LOXL2, LOXL3, LOXL4) and are useful in therapy, particularly in the treatment of cancer. Also disclosed are LOX inhibitors for use in the treatment of a cancer associated with EGFR and biomarkers that predict responsiveness to a LOX inhibitor.
-
公开(公告)号：US10544111B2
公开(公告)日：2020-01-28
申请号：US16230634
申请日：2018-12-21
IPC分类号： C07D263/46 , A61K31/415 , A61K31/421 , A61K31/4418 , A61K31/505 , C07D231/12 , C07D231/22 , C07D239/34 , C07D263/38 , C07D213/65 , A61P27/02 , C07D213/70 , C07K14/47 , C12N15/09
摘要： Provided is a heterocyclic compound having a superior RBP4-lowering action and useful as a medicament for the prophylaxis or treatment of a disease or symptom mediated by an increase in RBP4 or retinol supplied by RBP4.A compound represented by the formula (I): wherein each symbol is as defined in the Description, or a salt thereof has a superior RBP4-lowering action, and is useful as a medicament for the prophylaxis or treatment of a disease or symptom mediated by an increase in RBP4 or retinol supplied by RBP4.
-
公开(公告)号：US20190119224A1
公开(公告)日：2019-04-25
申请号：US16094499
申请日：2017-04-18
申请人： IFM Tre, Inc.
发明人： Gary Glick , Shomir Ghosh , William R. Roush
IPC分类号： C07D263/46 , C07D307/64 , C07D333/34 , C07D405/12 , C07D417/12
摘要： In one aspect, compounds of Formulae (I) and (II), or pharmaceutically acceptable salts thereof, are featured; Formula (I), Formula (II) or a pharmaceutically acceptable salt thereof, wherein the variables shown in Formulae (I) and (II) can be as defined anywhere herein.
-
-
-
-
-
-
-
-
-
搜索结果
234 条记录 (耗时 0.031 秒)
